Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
BIOA$5.96+2.76%
BioAge Labs, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$273.55M
Float & O/S:
Inst Own:
DilutionScan read 35 of BioAge Labs, Inc.'s SEC filings and found 3 warrant series, 2 convertibles, 1 ATM program, 3 shelf registrations and 4 completed offerings on file for BIOA. The latest dilution event on file is ATM sales on Jun 30, 2026. Analysis updated Oct 31, 2026.
Signal8 Summary
BIOA
Unprofitable biotech with comfortable cash runway
Snapshot
BioAge is a clinical-stage biotech burning cash to develop drugs for metabolic diseases. It reported $9M in revenue for FY 2025 but lost $80.6M. The company spends heavily on R&D, burning roughly $82M in free cash flow annually.
What's Happening Right Now
- : The stock fell following disappointing Phase 3 cardiovascular trial results from competitor Novo Nordisk, which sparked concerns about the broader NLRP3-targeting therapy class.
- : The company dosed the first participant in the Phase 2 QUELL-CV trial for BGE-102, evaluating the drug in patients with elevated cardiovascular risk, with topline data expected in the second half of 2026.
- : The company reported Q1 2026 financial results, highlighted positive Phase 1 data for BGE-102, and announced the completion of a $132.3 million follow-on public offering to bolster its balance sheet.
Raise routes on file: active ATM + effective shelf · latest dilution event 126 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
Jun 30, 2026 · ATM Sale
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Outstanding
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
ATM program
Issued 2025
Total capacity
Sold to date
Remaining capacity
- Sales agent
- Agreement date
- Commission
S-3 shelf registration
Issued 2025
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2025
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3ASR shelf registration
Issued 2026
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
Public offering
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Public offering
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
ATM block sale
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
ATM block sale
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Know who's about to sell into your BIOA trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
